Current and future management strategies for relapsed or progressive hepatoblastoma

被引：18
作者：
Rajkumar Venkatramani
Wayne L. Furman
Joerg Fuchs
Steven W. Warmann
Marcio H. Malogolowkin
机构：
[1] Division of HematologyOncology, Childrens Hospital Los Angeles, Los Angeles, CA
[2] Department of HematologyOncology, St Jude Childrens Research Hospital, Memphis, TN
[3] Department of Pediatric Surgery and Pediatric Urology, University of Tbingen, Tbingen
[4] Division of HematologyOncologyBone Marrow Transplant, Childrens Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI
来源：
Pediatric Drugs | 2012年 / 14卷 / 4期
关键词：
1-Phosphatidylinositol-3-kinase-inhibitors; Angiogenesis-inhibitors; Antineoplastics; Beta-Catenin-inhibitors; Bevacizumab; Carboplatin; Children; Cisplatin; Cyclophosphamide; Doxorubicin; Doxorubicin-liposomal; Epidermal-growth-factor-receptor-antagonists; Etoposide; Fluorouracil; fms-like-tyrosine-kinase-3-inhibitors; Gene-therapies; Hedgehog-cell-signalling-; pathway-inhibitors; Ifosfamide; Immunotherapies; Irinotecan; Liver cancer; Liver-transplant; mTOR-protein-inhibitors; Oxaliplatin; Pazopanib; Platelet-derived-growth-factor-receptor-antagonists; Poly(ADP-ribose)-polymerase- inhibitors; Proto-oncogene-protein-c-akt-inhibitors; Proto-oncogene-protein-c-kit inhibitors; Proto-oncogene-protein-c-met-inhibitors; Proto-oncogene-protein-c-ret-; inhibitors; Raf-kinase-inhibitors; Somatomedin inhibitors; Sorafenib; Sunitinib; Surgery; Vincristine; Wnt-signalling-pathway-inhibitors;
D O I：
10.2165/11597740-000000000-00000
中图分类号：
学科分类号：
摘要：
Hepatoblastoma is the most common primary malignant neoplasm of the liver in children. Improvements in chemotherapy and surgical techniques have increased survival rates for those with localized disease. The prognosis for patients with progressive or relapsed disease continues to be dismal. Complete resection by surgery or liver transplantation is necessary for cure. Few conventional chemotherapy agents have demonstrated activity in progressive or relapsed hepatoblastoma. Irinotecan has shown activity in relapsed and progressive hepatoblastoma. The efficacy of high-dose chemotherapy in this setting is unknown. Newer targeted agents that 'selectively' interfere with pathway targets involved in tumor growth and progression such as insulin-like growth factor, phosphatidylinositol 3-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR) are currently under development. Because of the rarity of hepatoblastoma, only a small minority of these agents will ever be evaluated in children with this disorder. Gene-directed therapy and immunotherapy have shown promising results in the preclinical setting, and should be investigated as future treatment options for advanced hepatoblastoma. © 2012 Springer International Publishing AG. All rights reserved.
引用
收藏
页码：221 / 232
页数：11
相关论文
共 135 条
[91]  
Racz I., Tory K., Gallyas Jr. F., Et al., BGP-15-A novel poly(ADP-ribose) polymerase inhibitor-protects against nephrotoxicity of cisplatin without compromising its antitumor activity, Biochem. Pharmacol., 63, 6, pp. 1099-1111, (2002)
[92]  
Rouleau M., Patel A., Hendzel M.J., Et al., PARP inhibition: PARP1 and beyond, Nat. Rev. Cancer, 10, 4, pp. 293-301, (2010)
[93]  
Wilhelm S., Carter C., Lynch M., Et al., Discovery and development of sorafenib: A multikinase inhibitor for treating cancer, Nat. Rev. Drug Discov., 5, 10, pp. 835-844, (2006)
[94]  
Heim M., Sharifi M., Hilger R.A., Et al., Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006, Int. J. Clin. Pharmacol. Ther., 41, 12, pp. 616-617, (2003)
[95]  
Abou-Alfa G.K., Johnson P., Knox J.J., Et al., Doxorubicin plus sorafenib vs doxorubicin alone in patients with adVanced hepatocellular carcinoma: A randomized trial, JAMA, 304, 19, pp. 2154-2160, (2010)
[96]  
Marsh A., Lo J., Cohen R.A., Et al., Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP, Pediatr. Blood Cancer.
[97]  
Powles T., Chowdhury S., Jones R., Et al., Sunitinib and other targeted therapies for renal cell carcinoma, Br. J. Cancer, 104, 5, pp. 741-745, (2011)
[98]  
Bukowski R.M., Pazopanib: A multikinase inhibitor with activity in adVanced renal cell carcinoma, Expert Rev. Anticancer Ther., 10, 5, pp. 635-645, (2010)
[99]  
Vilar E., Perez-Garcia J., Tabernero J., Pushing the envelope in the mTOR pathway: The second generation of inhibitors, Mol. Cancer Ther., 10, 3, pp. 395-403, (2011)
[100]  
Huynh H., Tyrosine kinase inhibitors to treat liver cancer, Expert Opin. Emerg Drugs, 15, 1, pp. 13-26, (2010)
567891011121314